Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2021
This article has no abstract
Epistemonikos ID: d2504225b1c1f1fe80854898913c28563c2ca910
First added on: Feb 13, 2025